Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

Clinical Trial Details

The purpose of this Phase 2 study is to determine the safety and effectiveness of study drug INCB054828 in treating subjects with a myeloproliferative or lymphoid neoplasm (a type of blood cancer that causes too many blood cells) that also have a genetic abnormality called 8p11. Currently, there is a great unmet need for treating this disease population. 

INCB054828 is an investigational drug, which means that INCB054828 has not been approved by the US Food and Drug Administration (FDA). 

This is an “open label” study. This means that you and the study research staff will know that you are receiving INCB054828. 

Key Eligibility: 
  • Men and women, aged 18 or older
  • Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation
  • Only subjects who are not candidates for stem cell transplantation and who have progressed and are not candidates for other disease-modifying therapies are eligible
  • Adequate performance status

Detailed eligibility will be reviewed when you contact the study team. 

Study contact by location

Upper East Side - Manhattan


Tania J. Curcio, NP, FNP-BC
(212) 746-2571

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




INCB 54828-203


Open to Enrollment

Age Group